Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Cognitive changes associated with endocrine therapy for breast cancer.

Agrawal K, Onami S, Mortimer JE, Pal SK.

Maturitas. 2010 Nov;67(3):209-14. doi: 10.1016/j.maturitas.2010.07.004. Epub 2010 Aug 4.

2.

Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.

Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.

J Clin Oncol. 2010 Mar 10;28(8):1294-300. doi: 10.1200/JCO.2008.21.3553. Epub 2010 Feb 8.

3.

Challenges in the endocrine management of breast cancer.

Mouridsen HT, Rose C, Brodie AH, Smith IE.

Breast. 2003 Aug;12 Suppl 2:S2-19. Review.

PMID:
14659138
4.

Emerging role of aromatase inhibitors in the adjuvant setting.

Goss PE.

Am J Clin Oncol. 2003 Aug;26(4):S27-33. Review.

PMID:
12902874
5.

The effects of hormone therapy on cognition in breast cancer.

Shilling V, Jenkins V, Fallowfield L, Howell T.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):405-12. Erratum in: J Steroid Biochem Mol Biol. 2005 Jun;96(1):93.

PMID:
14623538
6.

Preliminary data from ongoing adjuvant aromatase inhibitor trials.

Goss PE.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4397s-4401s; discussion 4411s-4412s. Review.

PMID:
11916231
7.

Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.

Mortimer JE, Urban JH.

Oncology (Williston Park). 2003 May;17(5):652-9; discussion 659, 662, 666 passim. Review.

8.
9.

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

Howell A, Howell SJ, Clarke R, Anderson E.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review.

PMID:
11850229
10.

Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.

Gradishar WJ.

Oncology. 2005;69(1):1-9. Epub 2005 Jul 28. Review.

PMID:
16088229
11.

Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

Buzdar A.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S42-8. Review.

PMID:
12756078
12.

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.

Morandi P, Rouzier R, Altundag K, Buzdar AU, Theriault RL, Hortobagyi G.

Cancer. 2004 Oct 1;101(7):1482-9. Review.

13.

Understanding the BIG results: Insights from the BIG 1-98 trial analyses.

Wardley AM.

Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Review.

PMID:
19096768
15.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
16.

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.

Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI.

Cancer Treat Rev. 2008 Apr;34(2):157-74. doi: 10.1016/j.ctrv.2007.11.001. Epub 2007 Dec 31. Review.

PMID:
18164821
17.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

18.

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU; ATAC Trialists' Group.

Lancet Oncol. 2008 Sep;9(9):866-72. doi: 10.1016/S1470-2045(08)70182-7. Epub 2008 Aug 12.

19.
20.

Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).

Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y.

Breast Cancer Res Treat. 2012 May;133(1):227-36. doi: 10.1007/s10549-011-1943-y. Epub 2012 Jan 11.

PMID:
22234519
Items per page

Supplemental Content

Write to the Help Desk